Abstract
Background: Migraine headaches are a severe and disabling
neurovascular disorder affecting nearly 20% of adults in the United States1.
Calcitonin Gene Related Peptide (CGRP) monoclonal antibodies (mAB) is a new
class of anti-migraine drugs that represent the first targeted therapy for the
prevention of migraine.